Negative cooperativity in binding of muscarinic receptor agonists and GDP as a measure of agonist efficacy

British Journal of Pharmacology

Volumn 162, Issue 5, 2011, Pages 1029-1044

  Jakubik J ^a   Janickova H ^a   El Fakahany, E E ^b   Dolezal V ^a  

^a INSTITUTE OF PHYSIOLOGY   (Czech Republic)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

agonist efficacy; GDP binding; muscarinic acetylcholine receptors

Indexed keywords

CARBACHOL; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); GUANOSINE DIPHOSPHATE; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; METHYLSCOPOLAMINE; MUSCARINIC AGENT; MUSCARINIC M2 RECEPTOR; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN; SULFUR 35; TRITIUM;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING KINETICS; BINDING SITE; CONTROLLED STUDY; DISSOCIATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTOR BINDING;

ALLOSTERIC REGULATION; ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; GTP-BINDING PROTEINS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); GUANOSINE DIPHOSPHATE; HUMANS; KINETICS; MUSCARINIC AGONISTS; MUSCARINIC ANTAGONISTS; N-METHYLSCOPOLAMINE; PROTEIN BINDING; RADIOLIGAND ASSAY; RECEPTOR, MUSCARINIC M2; RECOMBINANT PROTEINS; TRANSFECTION;

EID: 79551486842     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.01081.x     Document Type: Article

References (32)

1. Abdulaev NG, Ngo T, Ramon E, Brabazon DM, Marino JP, Ridge KD, (2006). The receptor-bound "empty pocket" state of the heterotrimeric G-protein alpha-subunit is conformationally dynamic. Biochemistry 45: 12986-12997.
2. Alexander SPH, Mathie A, Peters JA, (2009). Guide to receptors and channels (GRAC). 4th edn. Br J Pharmacol 158 (Suppl. 1): S1-S254.
3. Ashkenazi A, Winslow JW, Peralta EG, Peterson GL, Schimerlik MI, Capon DJ, et al. (1987). An M2 muscarinic receptor subtype coupled to both adenylyl cyclase and phosphoinositide turnover. Science 238: 672-675.
4. Birdsall NJ, Burgen AS, Hulme EC, (1978). The binding of agonists to brain muscarinic receptors. Mol Pharmacol 14: 723-736.
5. Burford NT, Tobin AB, Nahorski SR, (1995). Differential coupling of m1, m2 and m3 muscarinic receptor subtypes to inositol 1,4,5-trisphosphate and adenosine 3′,5′-cyclic monophosphate accumulation in Chinese hamster ovary cells. J Pharmacol Exp Ther 274: 134-142.
6. Burstein ES, Spalding TA, Brann MR, (1997). Pharmacology of muscarinic receptor subtypes constitutively activated by G proteins. Mol Pharmacol 51: 312-319.
7. Cheng Y, Prusoff WH, (1973). Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22: 3099-3108.
8. DeLapp NW, McKinzie JH, Sawyer BD, Vandergriff A, Falcone J, McClure D, et al. (1999). Determination of [35S]guanosine-5′-O-(3-thio)triphosphate binding mediated by cholinergic muscarinic receptors in membranes from Chinese hamster ovary cells and rat striatum using an anti-G protein scintillation proximity assay. J Pharmacol Exp Ther 289: 946-955.
9. De Lean A, Stadel JM, Lefkowitz RJ, (1980). A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. J Biol Chem 255: 7108-7117.
10. Ehlert FJ, (1988). Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol Pharmacol 33: 187-194.
11. Ferguson KM, Higashijima T, Smigel MD, Gilman AG, (1986). The influence of bound GDP on the kinetics of guanine nucleotide binding to G proteins. J Biol Chem 261: 7393-7399.
12. Florio VA, Sternweis PC, (1989). Mechanisms of muscarinic receptor action on Go in reconstituted phospholipid vesicles. J Biol Chem 264: 3909-3915.
13. Haga K, Haga T, Ichiyama A, (1986). Reconstitution of the muscarinic acetylcholine receptor. Guanine nucleotide-sensitive high affinity binding of agonists to purified muscarinic receptors reconstituted with GTP-binding proteins (Gi and Go). J Biol Chem 261: 10133-10140.
14. Hein P, Frank M, Hoffmann C, Lohse MJ, Bünemann M, (2005). Dynamics of receptor/G protein coupling in living cells. EMBO J 24: 4106-4114.
15. Hulme EC, Lu ZL, Saldanha JW, Bee MS, (2003). Structure and activation of muscarinic acetylcholine receptors. Biochem Soc Trans 31: 29-34.
16. Jakubík J, Bačáková L, el-Fakahany EE, Tuček S, (1995). Constitutive activity of the M1-M4 subtypes of muscarinic receptors in transfected CHO cells and of muscarinic receptors in the heart cells revealed by negative antagonists. FEBS Lett 377: 275-279.
17. Jakubík J, Bačáková L, Lisá V, el-Fakahany EE, Tuček S, (1996). Activation of muscarinic acetylcholine receptors via their allosteric binding sites. Proc Natl Acad Sci U S A 93: 8705-8709.
18. Jakubík J, Bačáková L, El-Fakahany EE, Tuček S, (1997). Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol 52: 172-179.
19. Jakubík J, El-Fakahany EE, Doležal V, (2006). Differences in kinetics of xanomeline binding and selectivity of activation of G proteins at M(1) and M(2) muscarinic acetylcholine receptors. Mol Pharmacol 70: 656-666.
20. Johnston CA, Siderovski DP, (2007). Receptor-mediated activation of heterotrimeric G-proteins: current structural insights. Mol Pharmacol 72: 219-230.
21. Kenakin T, (2003). Ligand-selective receptor conformations revisited: the promise and the problem. Trends Pharmacol Sci 24: 346-354.
22. Kent RS, De Lean A, Lefkowitz RJ, (1980). A quantitative analysis of beta-adrenergic receptor interactions: resolution of high and low affinity states of the receptor by computer modeling of ligand binding data. Mol Pharmacol 17: 14-23.
23. Michal P, Lysíková M, Tuček S, (2001). Dual effects of muscarinic M(2) acetylcholine receptors on the synthesis of cyclic AMP in CHO cells: dependence on time, receptor density and receptor agonists. Br J Pharmacol 132: 1217-1228. (Pubitemid 32234705)
24. Michal P, El-Fakahany EE, Doležal V, (2007). Muscarinic M2 receptors directly activate Gq/11 and Gs G-proteins. J Pharmacol Exp Ther 320: 607-614.
25. Oldham WM, Hamm HE, (2008). Heterotrimeric G protein activation by G-protein-coupled receptors. Nat Rev Mol Cell Biol 9: 60-71.
26. Seifert R, Wenzel-Seifert K, Gether U, Kobilka BK, (2001). Functional differences between full and partial agonists: evidence for ligand-specific receptor conformations. J Pharmacol Exp Ther 297: 1218-1226.
27. Shea L, Linderman JJ, (1997). Mechanistic model of G-protein signal transduction. Determinants of efficacy and effect of precoupled receptors. Biochem Pharmacol 53: 519-530.
28. Shiozaki K, Haga T, (1992). Effects of magnesium ion on the interaction of atrial muscarinic acetylcholine receptors and GTP-binding regulatory proteins. Biochemistry 31: 10634-10642.
29. Thomas TC, Schmidt CJ, Neer EJ, (1993). G-protein alpha o subunit: mutation of conserved cysteines identifies a subunit contact surface and alters GDP affinity. Proc Natl Acad Sci U S A 90: 10295-10298.
30. Tota MR, Schimerlik MI, (1990). Partial agonist effects on the interaction between the atrial muscarinic receptor and the inhibitory guanine nucleotide-binding protein in a reconstituted system. Mol Pharmacol 37: 996-1004.
31. Wenzel-Seifert K, Seifert R, (2000). Molecular analysis of beta(2)-adrenoceptor coupling to G(s)-, G(i)-, and G(q)-proteins. Mol Pharmacol 58: 954-966.
32. Wess J, (1997). G-protein-coupled receptors: molecular mechanisms involved in receptor activation and selectivity of G-protein recognition. FASEB J 11: 346-354.